Shire OKs Generic Version of Blockbuster Drug

Law360, New York (January 20, 2006, 12:00 AM EST) -- Shire Pharmaceuticals Group PLC has penned a settlement deal with generic challenger Impax over a blockbuster drug for hyperactivity.

The deal allows Impax, a California pharmaceutical company, to market a generic version of Adderall in the United States until Jan. 1, 2010 for a royalty fee from the sales. After that date, the U.K. drug maker plans to launch an alternative treatment for attention deficit disorder, which it hopes will make up for any loss of profits from Adderall.

The deal salvages sales of the top-selling...
To view the full article, register now.